| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 73 | 2025 | 258 | 14.710 |
Why?
|
| Hypoglycemic Agents | 55 | 2024 | 159 | 10.940 |
Why?
|
| Cardiovascular Diseases | 32 | 2025 | 154 | 8.120 |
Why?
|
| Diabetes Mellitus | 28 | 2024 | 170 | 7.960 |
Why?
|
| Anticholesteremic Agents | 17 | 2025 | 20 | 4.940 |
Why?
|
| Humans | 134 | 2025 | 4931 | 4.670 |
Why?
|
| Blood Glucose | 43 | 2024 | 179 | 4.620 |
Why?
|
| Endocrinology | 18 | 2019 | 18 | 3.260 |
Why?
|
| Dyslipidemias | 10 | 2023 | 18 | 2.790 |
Why?
|
| Insulin Glargine | 13 | 2024 | 15 | 2.710 |
Why?
|
| Hypolipidemic Agents | 9 | 2024 | 13 | 2.610 |
Why?
|
| Diabetes Complications | 11 | 2019 | 38 | 2.100 |
Why?
|
| Insulin | 19 | 2024 | 131 | 2.080 |
Why?
|
| Metabolic Syndrome | 7 | 2019 | 29 | 2.030 |
Why?
|
| Insulin Resistance | 8 | 2019 | 63 | 1.970 |
Why?
|
| Allylamine | 10 | 2012 | 10 | 1.830 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2025 | 276 | 1.830 |
Why?
|
| Prediabetic State | 12 | 2018 | 28 | 1.800 |
Why?
|
| Cholesterol, LDL | 13 | 2025 | 34 | 1.710 |
Why?
|
| Insulin, Long-Acting | 10 | 2018 | 14 | 1.690 |
Why?
|
| Obesity | 18 | 2023 | 189 | 1.630 |
Why?
|
| Risk Factors | 23 | 2023 | 593 | 1.520 |
Why?
|
| Treatment Outcome | 25 | 2024 | 402 | 1.490 |
Why?
|
| Societies, Medical | 15 | 2022 | 56 | 1.450 |
Why?
|
| Atherosclerosis | 5 | 2016 | 26 | 1.450 |
Why?
|
| United States | 33 | 2021 | 764 | 1.430 |
Why?
|
| Canagliflozin | 4 | 2019 | 5 | 1.430 |
Why?
|
| Peptides | 3 | 2019 | 14 | 1.410 |
Why?
|
| Glucagon-Like Peptide 1 | 5 | 2023 | 9 | 1.400 |
Why?
|
| Hypertension | 8 | 2023 | 123 | 1.330 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 14 | 1.320 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2020 | 4 | 1.320 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2025 | 42 | 1.280 |
Why?
|
| Aged | 20 | 2019 | 1188 | 1.260 |
Why?
|
| Female | 34 | 2025 | 2964 | 1.240 |
Why?
|
| Hypoglycemia | 12 | 2024 | 29 | 1.230 |
Why?
|
| Male | 30 | 2025 | 2620 | 1.200 |
Why?
|
| Metformin | 8 | 2024 | 30 | 1.190 |
Why?
|
| Metabolic Diseases | 4 | 2024 | 10 | 1.190 |
Why?
|
| Practice Guidelines as Topic | 8 | 2024 | 69 | 1.170 |
Why?
|
| Hypercholesterolemia | 5 | 2019 | 11 | 1.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2022 | 14 | 1.140 |
Why?
|
| Drug Therapy, Combination | 14 | 2024 | 58 | 1.100 |
Why?
|
| Glucosides | 4 | 2020 | 6 | 1.070 |
Why?
|
| Benzhydryl Compounds | 4 | 2020 | 13 | 1.060 |
Why?
|
| Middle Aged | 22 | 2025 | 1544 | 1.050 |
Why?
|
| Blood Glucose Self-Monitoring | 10 | 2023 | 27 | 0.970 |
Why?
|
| Algorithms | 11 | 2020 | 69 | 0.960 |
Why?
|
| Comprehensive Health Care | 3 | 2015 | 4 | 0.950 |
Why?
|
| Body Weight | 4 | 2018 | 80 | 0.950 |
Why?
|
| Triglycerides | 5 | 2022 | 45 | 0.940 |
Why?
|
| Double-Blind Method | 12 | 2024 | 81 | 0.940 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2024 | 2 | 0.930 |
Why?
|
| Myocardial Infarction | 2 | 2019 | 41 | 0.930 |
Why?
|
| Antibodies, Monoclonal | 3 | 2025 | 23 | 0.920 |
Why?
|
| Niacin | 3 | 2016 | 5 | 0.900 |
Why?
|
| Consensus | 15 | 2020 | 32 | 0.870 |
Why?
|
| Cholesterol, HDL | 4 | 2012 | 22 | 0.870 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 5 | 2023 | 6 | 0.850 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 407 | 0.800 |
Why?
|
| Adonis | 1 | 2022 | 1 | 0.780 |
Why?
|
| Amiodarone | 1 | 2022 | 3 | 0.780 |
Why?
|
| Ambulatory Care | 3 | 2018 | 18 | 0.770 |
Why?
|
| Risk Assessment | 4 | 2019 | 162 | 0.760 |
Why?
|
| Sitagliptin Phosphate | 3 | 2019 | 6 | 0.750 |
Why?
|
| Cardiovascular System | 1 | 2021 | 19 | 0.750 |
Why?
|
| Heart Failure | 4 | 2025 | 47 | 0.740 |
Why?
|
| Fasting | 3 | 2018 | 30 | 0.740 |
Why?
|
| Hyperlipidemias | 4 | 2018 | 15 | 0.730 |
Why?
|
| Hypertriglyceridemia | 2 | 2022 | 5 | 0.730 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 5 | 0.720 |
Why?
|
| Endocrinologists | 9 | 2020 | 9 | 0.710 |
Why?
|
| Risk Management | 1 | 2020 | 1 | 0.690 |
Why?
|
| Neoplasms | 2 | 2013 | 66 | 0.690 |
Why?
|
| Disease Management | 4 | 2020 | 23 | 0.680 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 58 | 0.660 |
Why?
|
| Adult | 20 | 2025 | 1402 | 0.640 |
Why?
|
| Albuminuria | 1 | 2019 | 24 | 0.640 |
Why?
|
| Bile Acids and Salts | 5 | 2011 | 8 | 0.630 |
Why?
|
| Fournier Gangrene | 1 | 2019 | 1 | 0.620 |
Why?
|
| Adamantane | 1 | 2019 | 1 | 0.620 |
Why?
|
| Dipeptides | 1 | 2019 | 6 | 0.620 |
Why?
|
| Brain Ischemia | 1 | 2019 | 9 | 0.620 |
Why?
|
| Biomedical Research | 1 | 2019 | 17 | 0.610 |
Why?
|
| Medicare | 1 | 2019 | 45 | 0.600 |
Why?
|
| Drug Administration Schedule | 9 | 2018 | 40 | 0.590 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 11 | 0.590 |
Why?
|
| Transitional Care | 1 | 2018 | 6 | 0.580 |
Why?
|
| Diabetic Nephropathies | 2 | 2017 | 39 | 0.570 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2017 | 1 | 0.560 |
Why?
|
| Pyrans | 1 | 2017 | 4 | 0.560 |
Why?
|
| Sulfonylurea Compounds | 1 | 2017 | 17 | 0.550 |
Why?
|
| Triazoles | 2 | 2014 | 12 | 0.530 |
Why?
|
| Benzazepines | 1 | 2016 | 1 | 0.530 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2016 | 1 | 0.530 |
Why?
|
| Pyrazines | 2 | 2014 | 16 | 0.530 |
Why?
|
| Colesevelam Hydrochloride | 10 | 2012 | 10 | 0.530 |
Why?
|
| Hyperglycemia | 5 | 2024 | 27 | 0.520 |
Why?
|
| Clinical Trials as Topic | 5 | 2015 | 37 | 0.510 |
Why?
|
| Thiazolidinediones | 3 | 2010 | 26 | 0.500 |
Why?
|
| Health Promotion | 2 | 2015 | 70 | 0.490 |
Why?
|
| Lipid Metabolism | 3 | 2015 | 28 | 0.490 |
Why?
|
| Lipids | 8 | 2017 | 34 | 0.470 |
Why?
|
| Receptors, Glucagon | 1 | 2014 | 1 | 0.450 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2025 | 7 | 0.450 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 18 | 0.440 |
Why?
|
| Insulin Infusion Systems | 5 | 2021 | 15 | 0.420 |
Why?
|
| Dietary Sucrose | 1 | 2013 | 4 | 0.410 |
Why?
|
| Beverages | 1 | 2013 | 5 | 0.410 |
Why?
|
| Lipodystrophy | 1 | 2013 | 3 | 0.410 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 49 | 0.400 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2025 | 17 | 0.390 |
Why?
|
| Young Adult | 7 | 2024 | 382 | 0.380 |
Why?
|
| Goals | 1 | 2012 | 6 | 0.380 |
Why?
|
| Adolescent | 7 | 2024 | 569 | 0.380 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2024 | 4 | 0.370 |
Why?
|
| Comorbidity | 3 | 2023 | 123 | 0.360 |
Why?
|
| Glucose | 4 | 2023 | 44 | 0.350 |
Why?
|
| Child | 7 | 2017 | 336 | 0.350 |
Why?
|
| Prognosis | 3 | 2020 | 167 | 0.340 |
Why?
|
| Biomarkers | 4 | 2020 | 160 | 0.330 |
Why?
|
| Proprotein Convertase 9 | 5 | 2025 | 5 | 0.330 |
Why?
|
| Incretins | 2 | 2010 | 2 | 0.320 |
Why?
|
| Kidney Diseases | 1 | 2011 | 113 | 0.310 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 202 | 0.310 |
Why?
|
| Life Style | 7 | 2018 | 44 | 0.300 |
Why?
|
| Congresses as Topic | 2 | 2019 | 16 | 0.300 |
Why?
|
| Animals | 6 | 2018 | 1369 | 0.290 |
Why?
|
| Weight Loss | 3 | 2016 | 32 | 0.290 |
Why?
|
| Aging | 2 | 2019 | 92 | 0.270 |
Why?
|
| Exercise | 2 | 2018 | 41 | 0.270 |
Why?
|
| Glomerular Filtration Rate | 2 | 2019 | 106 | 0.270 |
Why?
|
| Apolipoproteins B | 2 | 2024 | 6 | 0.260 |
Why?
|
| Drug Combinations | 4 | 2018 | 15 | 0.260 |
Why?
|
| Age Factors | 3 | 2017 | 152 | 0.250 |
Why?
|
| Naphthyridines | 1 | 2025 | 1 | 0.240 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2017 | 4 | 0.240 |
Why?
|
| Quality of Life | 4 | 2021 | 139 | 0.240 |
Why?
|
| Lipoproteins | 2 | 2017 | 7 | 0.240 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2024 | 2 | 0.230 |
Why?
|
| Lipoprotein(a) | 1 | 2024 | 3 | 0.230 |
Why?
|
| Linagliptin | 1 | 2024 | 1 | 0.230 |
Why?
|
| Mifepristone | 1 | 2024 | 8 | 0.230 |
Why?
|
| Cushing Syndrome | 1 | 2024 | 23 | 0.220 |
Why?
|
| Heart Diseases | 1 | 2023 | 7 | 0.220 |
Why?
|
| Primary Prevention | 2 | 2017 | 21 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 29 | 0.210 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 5 | 0.200 |
Why?
|
| Insulin Aspart | 2 | 2014 | 3 | 0.190 |
Why?
|
| Health Care Costs | 3 | 2018 | 30 | 0.190 |
Why?
|
| Time Factors | 3 | 2019 | 245 | 0.190 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 8 | 0.190 |
Why?
|
| Diagnostic Techniques, Endocrine | 2 | 2017 | 2 | 0.180 |
Why?
|
| China | 3 | 2024 | 5 | 0.170 |
Why?
|
| Hospitalization | 2 | 2019 | 106 | 0.170 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 17 | 0.160 |
Why?
|
| Frailty | 1 | 2019 | 7 | 0.160 |
Why?
|
| Blood Pressure | 4 | 2016 | 98 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 5 | 0.160 |
Why?
|
| Health Status | 2 | 2017 | 61 | 0.160 |
Why?
|
| Friends | 1 | 2019 | 4 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2019 | 6 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2019 | 10 | 0.160 |
Why?
|
| Terminology as Topic | 1 | 2019 | 7 | 0.160 |
Why?
|
| Recurrence | 1 | 2019 | 25 | 0.160 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 17 | 0.150 |
Why?
|
| Mentors | 1 | 2019 | 14 | 0.150 |
Why?
|
| Education, Medical | 1 | 2019 | 18 | 0.150 |
Why?
|
| Postprandial Period | 1 | 2018 | 3 | 0.150 |
Why?
|
| Survival Rate | 1 | 2019 | 92 | 0.150 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2018 | 2 | 0.150 |
Why?
|
| Glucagon-Like Peptides | 1 | 2018 | 3 | 0.150 |
Why?
|
| Glycemic Index | 1 | 2018 | 4 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 8 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2018 | 15 | 0.150 |
Why?
|
| Cause of Death | 1 | 2019 | 73 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2016 | 127 | 0.150 |
Why?
|
| Incidence | 1 | 2019 | 141 | 0.150 |
Why?
|
| Diet Therapy | 1 | 2018 | 3 | 0.140 |
Why?
|
| Glycation End Products, Advanced | 1 | 2017 | 3 | 0.140 |
Why?
|
| Fructosamine | 1 | 2017 | 3 | 0.140 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 1 | 0.140 |
Why?
|
| Somatosensory Disorders | 1 | 2017 | 1 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 34 | 0.140 |
Why?
|
| Endocrine System Diseases | 1 | 2017 | 6 | 0.140 |
Why?
|
| Primary Health Care | 2 | 2023 | 64 | 0.140 |
Why?
|
| Biological Products | 1 | 2017 | 4 | 0.140 |
Why?
|
| Serum Albumin | 1 | 2017 | 47 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2017 | 2 | 0.140 |
Why?
|
| Registries | 1 | 2017 | 53 | 0.140 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 12 | 0.140 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 5 | 0.140 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 4 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 12 | 0.140 |
Why?
|
| Fibric Acids | 1 | 2016 | 1 | 0.130 |
Why?
|
| Fenofibrate | 1 | 2016 | 2 | 0.130 |
Why?
|
| Retrospective Studies | 1 | 2019 | 513 | 0.130 |
Why?
|
| Overweight | 2 | 2014 | 23 | 0.130 |
Why?
|
| Culture | 1 | 2016 | 10 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2017 | 224 | 0.130 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 5 | 0.130 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2015 | 1 | 0.120 |
Why?
|
| Risk | 1 | 2014 | 39 | 0.110 |
Why?
|
| Kidney | 1 | 2015 | 165 | 0.100 |
Why?
|
| Bromocriptine | 1 | 2013 | 2 | 0.100 |
Why?
|
| Diabetic Angiopathies | 2 | 2010 | 10 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2012 | 8 | 0.100 |
Why?
|
| Global Health | 1 | 2012 | 44 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2011 | 18 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cholestyramine Resin | 1 | 2011 | 1 | 0.090 |
Why?
|
| Colestipol | 1 | 2011 | 1 | 0.090 |
Why?
|
| Epichlorohydrin | 1 | 2011 | 1 | 0.090 |
Why?
|
| Resins, Synthetic | 1 | 2011 | 1 | 0.090 |
Why?
|
| Imidazoles | 1 | 2011 | 10 | 0.090 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2011 | 12 | 0.090 |
Why?
|
| Government Agencies | 1 | 2010 | 1 | 0.090 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2010 | 1 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 7 | 0.090 |
Why?
|
| Europe | 1 | 2010 | 13 | 0.090 |
Why?
|
| Anemia | 1 | 2011 | 28 | 0.090 |
Why?
|
| Satiety Response | 1 | 2010 | 1 | 0.090 |
Why?
|
| Gastrointestinal Hormones | 1 | 2010 | 3 | 0.090 |
Why?
|
| MEDLINE | 1 | 2010 | 5 | 0.090 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 10 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2024 | 229 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2010 | 14 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2010 | 38 | 0.080 |
Why?
|
| Insulin Lispro | 1 | 2010 | 1 | 0.080 |
Why?
|
| United Kingdom | 1 | 2010 | 6 | 0.080 |
Why?
|
| Brain | 1 | 2010 | 78 | 0.080 |
Why?
|
| Smoking Cessation | 3 | 2018 | 21 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 17 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2009 | 60 | 0.080 |
Why?
|
| Abdominal Fat | 1 | 2008 | 6 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 7 | 0.080 |
Why?
|
| Acarbose | 1 | 2008 | 1 | 0.070 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 31 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 48 | 0.070 |
Why?
|
| Diet | 2 | 2014 | 95 | 0.070 |
Why?
|
| Cholesterol | 2 | 2022 | 29 | 0.070 |
Why?
|
| Glucose Intolerance | 2 | 2006 | 7 | 0.070 |
Why?
|
| Critical Care | 1 | 2007 | 8 | 0.070 |
Why?
|
| Liraglutide | 2 | 2018 | 2 | 0.070 |
Why?
|
| Mice | 1 | 2008 | 555 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 40 | 0.060 |
Why?
|
| Hormone Antagonists | 1 | 2024 | 4 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 5 | 0.060 |
Why?
|
| Insulin Antibodies | 1 | 2024 | 3 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2024 | 30 | 0.060 |
Why?
|
| Prevalence | 1 | 2024 | 184 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 66 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2022 | 2 | 0.050 |
Why?
|
| Specialization | 1 | 2022 | 14 | 0.050 |
Why?
|
| Diet, Fat-Restricted | 2 | 2012 | 2 | 0.050 |
Why?
|
| Cost Savings | 2 | 2012 | 12 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2012 | 7 | 0.050 |
Why?
|
| Motor Activity | 2 | 2012 | 24 | 0.050 |
Why?
|
| Technology | 1 | 2021 | 2 | 0.050 |
Why?
|
| Symporters | 1 | 2020 | 1 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 37 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 19 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 4 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 13 | 0.040 |
Why?
|
| Health Surveys | 1 | 2018 | 55 | 0.040 |
Why?
|
| Systems Integration | 1 | 2018 | 8 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 14 | 0.040 |
Why?
|
| Triazines | 1 | 2018 | 5 | 0.040 |
Why?
|
| Counseling | 1 | 2018 | 11 | 0.040 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 3 | 0.040 |
Why?
|
| Sleep | 1 | 2018 | 11 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2018 | 135 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 22 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 9 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 18 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 62 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2016 | 10 | 0.030 |
Why?
|
| Costa Rica | 1 | 2016 | 1 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 1 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 2 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 6 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 137 | 0.030 |
Why?
|
| Mass Screening | 1 | 2017 | 82 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2016 | 6 | 0.030 |
Why?
|
| District of Columbia | 1 | 2015 | 2 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2015 | 5 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2015 | 1 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 3 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 85 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2014 | 14 | 0.030 |
Why?
|
| American Medical Association | 1 | 2014 | 1 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2014 | 1 | 0.030 |
Why?
|
| Weight Reduction Programs | 1 | 2014 | 1 | 0.030 |
Why?
|
| Patient Safety | 1 | 2014 | 8 | 0.030 |
Why?
|
| Occupational Health | 1 | 2014 | 3 | 0.030 |
Why?
|
| Anti-Obesity Agents | 1 | 2014 | 2 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2014 | 7 | 0.030 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 10 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 36 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 53 | 0.030 |
Why?
|
| Decision Trees | 1 | 2013 | 5 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2012 | 5 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2011 | 30 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2011 | 47 | 0.020 |
Why?
|
| Science | 1 | 2010 | 1 | 0.020 |
Why?
|
| Infusions, Subcutaneous | 1 | 2010 | 1 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2010 | 2 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 3 | 0.020 |
Why?
|
| Iron | 1 | 2011 | 33 | 0.020 |
Why?
|
| Ghrelin | 1 | 2010 | 3 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2010 | 7 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 17 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Leptin | 1 | 2010 | 17 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 46 | 0.020 |
Why?
|
| Health Personnel | 1 | 2010 | 40 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 358 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2007 | 4 | 0.020 |
Why?
|
| Pregnancy in Diabetics | 1 | 2007 | 6 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 15 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2007 | 15 | 0.020 |
Why?
|
| Health Behavior | 1 | 2007 | 43 | 0.020 |
Why?
|
| Nutrition Therapy | 1 | 2007 | 13 | 0.020 |
Why?
|
| Information Systems | 1 | 2006 | 11 | 0.020 |
Why?
|
| Pregnancy | 1 | 2007 | 417 | 0.020 |
Why?
|
| Internet | 1 | 2006 | 22 | 0.020 |
Why?
|